公开(公告)号：US20110112178A1

公开(公告)日：2011-05-12

申请号：US12982261

申请日：2010-12-30

Applicant: Antonin de Fougerolles ,  Andrew Sprague ,  Jens Harborth ,  Maria Gabriela Belvisi ,  Mark Andrew Birrell ,  Elizabeth Ouise Hardaker ,  Matthew Copeland Catley

Inventor： Antonin de Fougerolles ,  Andrew Sprague ,  Jens Harborth ,  Maria Gabriela Belvisi ,  Mark Andrew Birrell ,  Elizabeth Ouise Hardaker ,  Matthew Copeland Catley

IPC: A61K31/713 ,  C07H21/02 ,  C12N15/63 ,  C12N5/00 ,  A61P29/00

CPC classification number: C12N15/1137 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3515 ,  C12Y207/1101 ,  C12N2310/3521

Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.

Abstract translation: 本发明涉及用于抑制IKK-B基因表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸，长度通常为19-25个核苷酸的核苷酸序列的反义链，以及 其基本上与IKK-B基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由IKK-B基因的表达或活化引起的疾病的方法; 以及抑制细胞中IKK-B基因表达的方法。

公开(公告)号：US07737265B2

公开(公告)日：2010-06-15

申请号：US11477028

申请日：2006-06-27

Applicant: Akin Akinc ,  Antonin De Fougerolles ,  Hans-Peter Vornlocher ,  Philipp Hadwiger ,  Birgit Bramlage

Inventor： Akin Akinc ,  Antonin De Fougerolles ,  Hans-Peter Vornlocher ,  Philipp Hadwiger ,  Birgit Bramlage

IPC: C07H21/02 ,  C07H21/04 ,  C12Q1/68 ,  C12P19/34 ,  C12N15/63

CPC classification number: C12N15/113 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3521

Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1α, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.

Abstract translation: 本发明的特征涉及用于调节HIF-1α表达的化合物，组合物和方法，例如通过RNA干扰（RNAi）机制。 化合物和组合物包括可以未修饰或化学修饰的iRNA试剂。

公开(公告)号：US20090324598A1

公开(公告)日：2009-12-31

申请号：US12268459

申请日：2008-11-11

Applicant: Philip Gotwals ,  Antonin De Fougerolles ,  Roy Lobb ,  Victor Kotelianski

Inventor： Philip Gotwals ,  Antonin De Fougerolles ,  Roy Lobb ,  Victor Kotelianski

IPC: A61K39/395

CPC classification number: C07K16/2842 ,  A61K2039/505 ,  C07K16/2821 ,  C07K16/2839 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76

Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.

Abstract translation: 公开了治疗炎症性疾病的方法，特别是治疗关节炎。 该方法包括施用能够结合VLA-1表位的功能阻断抗体。

公开(公告)号：US20090047217A1

公开(公告)日：2009-02-19

申请号：US11943501

申请日：2007-11-20

Applicant: Cynthia Green ,  Victor Kotelianski ,  Antonin de Fougerolles ,  John Carulli ,  Catherine Hession

Inventor： Cynthia Green ,  Victor Kotelianski ,  Antonin de Fougerolles ,  John Carulli ,  Catherine Hession

IPC: A61K49/00 ,  C07K14/00 ,  C07K16/18 ,  C12P21/00 ,  A61P37/04 ,  G01N33/566 ,  A61K39/395 ,  A61K38/17

CPC classification number: C07K14/70532 ,  A61K38/00 ,  Y10S435/81

Abstract: The present invention provides novel isolated BLAA polynucleotides and the membrane-associated or secreted polypeptides encoded by the BLAA polynucleotides. Also provided are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, variant, mutant or fragment of the BLAA polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BLAA polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

Abstract translation: 本发明提供新的分离的BLAA多核苷酸和由BLAA多核苷酸编码的膜相关或分泌的多肽。 还提供了免疫特异性结合BLAA多肽或BLAA多肽，多核苷酸或抗体的任何衍生物，变体，突变体或片段的抗体。 本发明另外提供了其中BLAA多肽，多核苷酸和抗体用于检测和治疗广泛范围的病理状态以及其它用途的方法。